Fabio Conforti

8PUBLICATIONS
56CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer cell biologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 15, 2026
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study.

Carmine Valenza, Yue Zheng, Monica Milano

|Sep 17, 2025
Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.

Fabio Conforti, Federico Merlo, Laura Pala

|Jul 02, 2025
Reply to: "Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials" and "Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer".

Fabio Conforti, Vincenzo Bagnardi, Isabella Sala

|Jan 30, 2025
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.

Fabio Conforti, Valentina Nekljudova, Isabella Sala

|Oct 31, 2023
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research.

Fabio Conforti, Laura Pala, Tommaso De Pas

|Dec 22, 2021
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.

Fabio Conforti, Laura Pala, Isabella Sala

Pageof 2

Frequent Collaborators

4 joint publications

Tommaso De Pas

4 joint publications

Vincenzo Bagnardi

4 joint publications

Richard Gelber

3 joint publications

Laura Pala